Harvard Bioscience Profit Margin

Harvard Bioscience (HBIO) currently reports a profit margin of -11.44% as of March 2026. That compares with -63.52% in the prior-year period — up 82.0% year over year. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore Harvard Bioscience's profit margin history and peer comparisons.

Harvard Bioscience's profit margin increased from -63.52% to -11.44% — a 82.0% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Harvard Bioscience's profit margin of -11.44% is lower than the Healthcare sector average of 14.34%. That is roughly 179.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Harvard Bioscience's current -11.44% should be judged against Healthcare norms (sector average: 14.34%) and against HBIO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -11.44%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Harvard Bioscience, and consider following HBIO for alerts when major investors trade the stock.